Risultati per: Standard di cura nel diabete 2024

Introduction
Linezolid is a broadly used antibiotic to treat complicated infections caused by gram-positive bacteria. Therapeutic drug monitoring of linezolid concentrations is recommended to maximise its efficacy and safety, mainly haematological toxicity. Different pharmacokinetic/pharmacodynamic targets have been proposed to improve linezolid exposure: the ratio of the area under the concentration–time curve during a 24-hour period to minimum inhibitory concentration (MIC) between 80 and 120; percentage of time that the drug concentration remains above the MIC during a dosing interval greater than 85% and the trough concentration between 2 and 7 mg/L. This clinical trial aims to evaluate the safety, efficacy and the clinical and economic utility of personalised dosing of linezolid using Bayesian forecasting methods to attain pharmacokinetic/pharmacodynamic targets, known as model-informed precision dosing.

Methods and analysis
This is a pragmatic, multicentre, randomised, parallel, controlled, phase IV and low intervention trial. Participants will be randomly assigned 1:1 to each group (n=346 per group). Control group will receive the standard dose of linezolid. Intervention group will receive personalised dosage of linezolid based on pharmacokinetic–pharmacodynamic adjustments. The primary outcome will be the incidence of thrombocytopenia in both groups.

Ethics and dissemination
This protocol was approved by the Ethical Committee of the Investigation with Medicines of Galicia (code 2022/140) and authorised by the Spanish Agency for Medicines and Medical Devices. The trial is implemented in accordance with the Declaration of Helsinki and the international ethical and scientific quality standard, the Good Clinical Practice. The results will be published in peer-reviewed journals.

Trial registration number
EudraCT registration code: 2022-000144-30.

The UK Congress of Obesity (UKCO) is an annual conference of the Association for the study of Obesity (ASO), a charitable organisation that aims to understand obesity and its prevention and treatment. The ninth UKCO took place on September 24–25, 2024, at Rhodes House in Oxford, UK, with the theme of “Breaking barriers: shaping the future of obesity prevention and management”. Through a range of posters, presentations, and discussions, the programme covered a variety of topics under this theme, including, new and emerging treatments for obesity, the role of the food environment and food policy, barriers to accessing treatment, childhood and adolescent obesity, obesity policy, and food insecurity and obesity.

Agenas, 8 milioni di ricoveri, convive alta e bassa qualità cure

Una simulazione per sensibilizzare sull’impatto emotivo e psicologico

Illustrato Bilancio sociale. Parte secondo lotto della Biobanca

Illustrato Bilancio sociale. Parte secondo lotto della Biobanca

Illustrato Bilancio sociale. Parte secondo lotto della Biobanca

Illustrato Bilancio sociale. Parte secondo lotto della Biobanca

Stroke, Volume 55, Issue 11, Page 2589-2589, November 1, 2024.

Perdita di funzionalità del compartimento staminale è più veloce

Con tipo 2 raddoppia rischio Alzheimer e demenza vascolare

Un ‘doppio diabete’ che può accelerare distruzione cellule Beta

Oncologia pediatrica sostenuta da chef Romito e da Jre-Italia

Eccessiva crescita fetale, parto pretermine per aumento del glucosio

Introduction
First-line oxygenation strategy in patients with acute hypoxaemic respiratory failure consists in standard oxygen or high-flow nasal oxygen therapy. Clinical practice guidelines suggest the use of high-flow nasal oxygen rather than standard oxygen. However, findings remain contradictory with a low level of certainty. We hypothesise that compared with standard oxygen, high-flow nasal oxygen may reduce mortality in patients with acute hypoxaemic respiratory failure.

Method and analysis
The Standard Oxygen versus High-flow nasal Oxygen-trial is an investigator-initiated, multicentre, open-label, randomised controlled trial comparing high-flow nasal oxygen versus standard oxygen in patients admitted to an intensive care unit (ICU) for acute respiratory failure with moderate-to-severe hypoxaemia. 1110 patients will be randomly assigned to one of the two groups with a ratio of 1:1. The primary outcome is the number of patients who died 28 days after randomisation. Secondary outcomes include comfort, dyspnoea and oxygenation 1 hour after treatment initiation, the number of patients intubated at day 28, mortality in ICU, in hospital and until day 90, and complications during ICU stay.

Ethics and dissemination
The study has been approved by the central Ethics Committee ‘Sud Méditerranée III’ (2020-07-05) and patients will be included after informed consent. The results will be submitted for publication in peer-reviewed journals.

Trial registration number
NCT04468126.

Important presentations for generalists